Order Article Reprints

Tanaka T, Takata K, Yokoyama K, Fukuda H, Yamauchi R, Fukunaga A, Shakado S, Sakisaka S, Hirai F. Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology. 2022; 29(7):4799-4810. https://doi.org/10.3390/curroncol29070381

Tanaka, Takashi, Kazuhide Takata, Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Atsushi Fukunaga, Satoshi Shakado, Shotaro Sakisaka, and Fumihito Hirai. 2022. "Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma" Current Oncology 29, no. 7: 4799-4810. https://doi.org/10.3390/curroncol29070381

Tanaka, T., Takata, K., Yokoyama, K., Fukuda, H., Yamauchi, R., Fukunaga, A., Shakado, S., Sakisaka, S., & Hirai, F. (2022). Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology, 29(7), 4799-4810. https://doi.org/10.3390/curroncol29070381